Recent studies have shown that inhibiting PPT1, a target for chloroquine derivatives such as hydroxychloroquine (HCQ) or GNS561, significantly boosts the antitumor effects of anti-PD-1 antibodies in melanoma treatment.249. The gene discussed is PPT1; the disease is melanoma.